Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) have been assigned a consensus recommendation of “Moderate Buy” from the six ratings firms that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $7.0833.

Several equities research analysts recently commented on XERS shares. Leerink Partners boosted their price objective on shares of Xeris Biopharma from $7.00 to $9.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 19th. Wall Street Zen lowered shares of Xeris Biopharma from a “strong-buy” rating to a “buy” rating in a research report on Friday, September 5th. Finally, HC Wainwright started coverage on shares of Xeris Biopharma in a research report on Tuesday, August 12th. They issued a “buy” rating and a $10.00 price objective on the stock.

Insider Buying and Selling at Xeris Biopharma

In related news, Director Jeffrey W. Sherman sold 42,232 shares of the business’s stock in a transaction dated Thursday, August 28th. The shares were sold at an average price of $7.92, for a total value of $334,477.44. Following the completion of the transaction, the director owned 219,188 shares of the company’s stock, valued at approximately $1,735,968.96. The trade was a 16.15% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Marla Persky sold 15,500 shares of the business’s stock in a transaction dated Thursday, September 11th. The shares were sold at an average price of $7.72, for a total transaction of $119,660.00. Following the completion of the transaction, the director directly owned 142,000 shares of the company’s stock, valued at $1,096,240. The trade was a 9.84% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 207,732 shares of company stock valued at $1,550,437 over the last 90 days. 6.47% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its stake in Xeris Biopharma by 2.7% in the 1st quarter. Vanguard Group Inc. now owns 8,109,644 shares of the company’s stock valued at $44,522,000 after purchasing an additional 210,581 shares during the last quarter. Geode Capital Management LLC raised its stake in Xeris Biopharma by 7.2% in the 2nd quarter. Geode Capital Management LLC now owns 3,650,688 shares of the company’s stock valued at $17,052,000 after purchasing an additional 244,862 shares during the last quarter. Qube Research & Technologies Ltd raised its stake in Xeris Biopharma by 67.5% in the 2nd quarter. Qube Research & Technologies Ltd now owns 3,089,771 shares of the company’s stock valued at $14,429,000 after purchasing an additional 1,245,188 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in Xeris Biopharma by 75.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company’s stock valued at $15,317,000 after purchasing an additional 1,199,435 shares during the last quarter. Finally, Millennium Management LLC raised its stake in Xeris Biopharma by 19.0% in the 1st quarter. Millennium Management LLC now owns 2,317,972 shares of the company’s stock valued at $12,726,000 after purchasing an additional 369,420 shares during the last quarter. Institutional investors and hedge funds own 42.75% of the company’s stock.

Xeris Biopharma Stock Performance

Shares of NASDAQ XERS opened at $7.36 on Thursday. The firm has a market capitalization of $1.19 billion, a P/E ratio of -35.05 and a beta of 0.13. Xeris Biopharma has a one year low of $2.69 and a one year high of $8.03. The company’s fifty day moving average is $6.54 and its two-hundred day moving average is $5.32.

Xeris Biopharma (NASDAQ:XERS) last issued its earnings results on Thursday, August 7th. The company reported ($0.01) EPS for the quarter, topping the consensus estimate of ($0.03) by $0.02. The company had revenue of $67.71 million for the quarter, compared to analysts’ expectations of $64.58 million. On average, sell-side analysts forecast that Xeris Biopharma will post -0.41 earnings per share for the current fiscal year.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.